Lymphopenia can be a useful biomarker of adverse events related to vemurafenib

J Eur Acad Dermatol Venereol. 2017 Jan;31(1):e24-e26. doi: 10.1111/jdv.13591. Epub 2016 Jan 25.

Authors

K Imafuku¹, K Yoshino¹, K Ishiwata¹, K Ymaguchi¹, S Tsuboi¹, K Ohara¹, H Hata²

Affiliations

¹ Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Tokyo, Japan.
² Department of Dermatology, Hokkaido University Graduate School of Medicine, Sapporo, Japan.

PMID: 26810349
DOI: 10.1111/jdv.13591

No abstract available

Publication types

Letter

MeSH terms

Adult
Aged
Antineoplastic Agents / adverse effects*
Biomarkers / metabolism*
Female
Humans
Indoles / adverse effects*
Lymphopenia / physiopathology*
Male
Middle Aged
Sulfonamides / adverse effects*
Vemurafenib

Substances

Antineoplastic Agents
Biomarkers
Indoles
Sulfonamides
Vemurafenib